… patients with heart failure and a left ventricular ejection fraction of more than 40% to receive
dapagliflozin (… ; had stabilized heart failure, with or without type 2 diabetes mellitus; had a left …

… Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes, which
is … SGLT2 inhibitors (including dapagliflozin) in HFrEF with or without diabetes mellitus (DM). …

… 4017 patients of whom 2019 were assigned to dapagliflozin … in significantly more wins for
dapagliflozin than for placebo (win … trial: dapagliflozin in patients without diabetes mellitus with …

… patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease
to receive either dapagliflozin or … Diabetes mellitus is estimated to affect more than 415 …

… dapagliflozin showed that treatment with dapagliflozin of T2DM patients at risk for atherosclerotic
cardiovascular disease … dapagliflozin reduced the risk of worsening HF or death from …

… incidence of diabetes. We assessed the effect of dapagliflozin on new-onset type 2 diabetes
in a … drugs on the incidence of diabetes mellitus among patients with hypertensive kidney …

… 10 mg/day significantly reduced the risk of CV death or hospitalization for HF in patients
with type 2 diabetes mellitus (T2DM) who had or were at risk for atherosclerotic CV …

… Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces cardiovascular death
and worsening heart failure in patients … , randomized trial of dapagliflozin early in AHF …

… reasons other than death occurred in 15 dapagliflozin-treated and 13 placebo-treated
patients, resulting in 146 and 145 patients in the dapagliflozin and placebo groups, respectively, …

… and mortality in patients with Type 2 diabetes and concurrent heart failure, acute MI and
renal failure are likely to see the usage of dapagliflozin in patients with these comorbidities …